USFDA approves drug for severe Itching in kidney disease patients

The drug is designed to be administered three times a week after each dialysis.

Medicine Vaccine Syringe
Picture: Pixabay

Last Updated on August 26, 2021 by The Health Master

The United States Food and Drug Administration (USFDA) yesterday approved Cara Therapeutics’s (CARA.O) drug to treat moderate-to-severe itching in patients with chronic kidney disease undergoing dialysis, making it the first therapy for the ailment in the United States.

The company expects to commercially launch the injection, Korsuva, in the first quarter of 2022, Derek Chalmers, Chief Executive Officer, Cara Therapeutics, said in an interview.

The drug is designed to be administered three times a week after each dialysis. It reduces the activity of the sensory nerve that relays itching from the skin to the spinal cord and subsequently to the brain.

Chronic kidney disease patients with severe itching currently take depressants such as barbiturates and allergy medication antihistamines.

Zydus Cadila gets USFDA nod for Tofacitinib ER Tablets

GSK gets USFDA nod for Jemperli to treat advanced solid Tumours

Lupin gets tentative USFDA nod for Brivaracetam tablets

Zydus Cadila gets USFDA nod for Mesalamine ER capsules

Cipla gets USFDA nod for generic Difluprednate Ophthalmic Emulsion

Alembic gets USFDA nod for Clomipramine HCL Capsules

Latest Notifications regarding Pharmaceuticals

Proposed Pharma cluster: Rs 400 crore investment

Pfizer becomes first Covid vaccine globally to get full USFDA approval

3 Labs booked for Prenatal testing without permission

J&J submits application to CDSCO for study of Covid-19 vaccine on…

High court denied bail in Drug seizure case

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
YouTube Icon

Enter your email address:

Delivered by FeedBurner